Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, raised $200 million by offering 14.3 million shares (up from the 13.3 million previously anticipated) at $14, the low end of the range of $14 to $16. Orchard Therapeutics will list on the Nasdaq under the symbol ORTX. J.P. Morgan, Goldman Sachs and Cowen acted as lead managers on the deal.
